Cargando…
Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease
BACKGROUND: Bone destruction is a feature of multiple myeloma, characterised by osteolytic bone destruction due to increased osteoclast activity and suppressed or absent osteoblast activity. Almost all multiple myeloma patients develop osteolytic bone lesions associated with severe and debilitating...
Autores principales: | Dowling, Paul, Hayes, Catriona, Ting, Kay Reen, Hameed, Abdul, Meiller, Justine, Mitsiades, Constantine, Anderson, Kenneth C, Clynes, Martin, Clarke, Colin, Richardson, Paul, O’Gorman, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213504/ https://www.ncbi.nlm.nih.gov/pubmed/25322877 http://dx.doi.org/10.1186/1471-2164-15-904 |
Ejemplares similares
-
Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients
por: Ting, Kay Reen, et al.
Publicado: (2017) -
Bone Disease in Multiple Myeloma: Pathophysiology and Management
por: Hameed, Abdul, et al.
Publicado: (2014) -
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010) -
The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010) -
Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach
por: Katsenou, Angeliki, et al.
Publicado: (2023)